Ignite Creation Date:
2025-12-25 @ 3:52 AM
Ignite Modification Date:
2025-12-26 @ 2:41 AM
Study NCT ID:
NCT00639002
Status:
COMPLETED
Last Update Posted:
2018-02-13
First Post:
2008-03-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
Sponsor:
Incyte Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-03
Start Date Type:
None
Primary Completion Date:
2010-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-07
Completion Date Type:
ACTUAL
First Submit Date:
2008-03-12
First Submit QC Date:
None
Study First Post Date:
2008-03-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2011-12-16
Results First Submit QC Date:
None
Results First Post Date:
2012-01-23
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2010-06-22
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2018-01-15
Last Update Post Date:
2018-02-13
Last Update Post Date Type:
ACTUAL